Copper mixed ligand complexes were created with the goal of using them as anticancer agents. Different physicochemical approaches were used to characterise the complexes, including elemental analysis, TG-DTA, 1H NMR, IR, and uv-visible spectroscopy. All compounds designated by physicochemical techniques have the molecular formula [Cu (Ala) (CCA)].2H2O, [Cu (Gly)(CCA)]. 2H2O [Cu (Ser)(CCA)].2H2O [Cu (Cys)(CCA)].2H2O [Cu (Ser)(CCA)].2H2O [Cu (Cys)(CCA)].2H2O [Cu (Ser)(CCA)].2H2O The particle size of all complexes was measured using NTA and found to be between 56 and 83 nanometres. The cytotoxic activity of all complexes on the MCF-7 cell line was determined using the MTT test technique, revealing that they are effective anti-breast cancer drugs. In comparison to alanine and glycine, the mixed ligand combination of serine and glycine was reported to have greater cytotoxicity against the MCF-7 cell line. It might be due to the free –OH and –SH groups found in serine and cysteine, which indicate appropriate DNA binding. We concluded that freshly manufactured mixed ligand complexes comprising amino acids had a larger cytotoxic impact than the CCA complex based on cytotoxic assessment results. It's possible that this is because the amino acids in the complexes have a high affinity for DNA.